Post-transplant Lymphoproliferative Disorder (PTLD): Infection, Cancer?

被引：0
作者：
Voorhees T.J. [1 ]
Baiocchi R.A. [1 ,2 ]
机构：
[1] Department of Internal Medicine, Division of Hematology, Ohio State University College of Medicine, 460 West 10th Avenue, Columbus, 43210, OH
[2] Division of Hematology, The Ohio State University, 320 West 10th Avenue, Columbus, 43210, OH
来源：
Current Transplantation Reports | 2016年 / 3卷 / 2期
关键词：
EBV; EBV oncogenesis; EBV transformation; Post-transplant lymphoproliferative disorder;
D O I：
10.1007/s40472-016-0102-0
中图分类号：
学科分类号：
摘要：
Post-transplant lymphoproliferative disorder encompasses a broad spectrum of lymphoid disorders that occur in immune-suppressed patients following solid or hematopoietic stem cell transplantation. The Epstein-Barr virus (EBV) is an oncogenic virus capable of transforming B lymphocytes and is associated with the pathogenesis of multiple benign and malignant lymphoproliferative disorders, including PTLD. This review outlines current knowledge of EBV pathogenesis, its role in B cell immortalization, transformation, and as an etiologic agent in lymphoproliferative disorders in immune-suppressed patients following transplantation. Here, we provide discussion incorporating infectious disease and medical oncology aspects. © 2016, Springer International Publishing AG.
引用
收藏
页码：145 / 153
页数：8
相关论文
共 106 条
[1]  
Penn I., Hammond W., Brettschneider L., Et al., Malignant lymphomas in transplantation patients, Transplant Proc, 1, 1, pp. 106-112, (1969)
[2]  
Taylor A.L., Marcus R., Bradley J.A., Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation, Crit Rev Oncol Hematol, 56, 1, pp. 155-167, (2005)
[3]  
Cockfield S.M., Identifying the patient at risk for post-transplant lymphoproliferative disorder, Transpl Infect Dis, 3, 2, pp. 70-78, (2001)
[4]  
Gao S.Z., Chaparro S.V., Perlroth M., Et al., Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University, J Heart Lung Transplant.
[5]  
Han C.W., Imamura M., Hashino S., Et al., Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression, Bone Marrow Transplant, 15, 5, pp. 733-739, (1995)
[6]  
Hojo M., Morimoto T., Maluccio M., Et al., Cyclosporine induces cancer progression by a cell-autonomous mechanism, Nature, 397, 6719, pp. 530-534, (1999)
[7]  
Cox K.L., Lawrence-Miyasaki L.S., Garcia-Kennedy R., Et al., An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation, Transplantation, 59, 4, pp. 524-529, (1995)
[8]  
Crane G.M., Powell H., Kostadinov R., Et al., Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage, Oncotarget, 6, 32, pp. 33849-33866, (2015)
[9]  
Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., Et al., Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients, N Engl J Med, 323, 25, pp. 1723-1728, (1990)
[10]  
Opelz G., Dohler B., Lymphomas after solid organ transplantation: a collaborative transplant study report, Am J Transplant, 4, 2, pp. 222-230, (2004)
12345678910